The execs at Haleon, a huge multinational consumer products company, ought to take a good look in the mirror. That is, unless ...

While Trump's tariffs could have a broad impact on healthcare prices, it is likely they will not have the devastating result that some may be expecting, health policy and trade experts say.

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

Repurposing current drugs to tackle dementia is an ‘urgent priority’, academics say, but other experts warn more work is needed before they can be used to help treat the disease ...

“Non-steroidal anti-inflammatory drugs, or NSAIDs, like ibuprofen, and naproxen and Motrin, treat actual inflammation,” Brown explained. “So they’re blocking an enzyme to prevent any ongoing ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

This new nonaddictive alternative is the first of its kind that interrupts the pain signal before it reaches the brain.

indigestion drug lansoprazole, and those taking a multivitamin also saw benefits. The migraine treatment amitriptyline was also linked to the biggest negative effects. Ibuprofen can increase the ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...